Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders (Q37329136)

19 August 2017

1 reference

title

Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders (English)

1 reference

19 August 2017

1 reference

1 reference

Anthony N Vo

1

1 reference

19 August 2017

Moti L Kashyap

series ordinal

2

1 reference

19 August 2017

publication date

1 November 2008

1 reference

Expert Review of Cardiovascular Therapy

19 August 2017

published in

1 reference

19 August 2017

volume

6

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

1303-1310

1 reference

Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Niacin therapy in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Influence of nicotinic acid on serum cholesterol in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

The benefits of niacin in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

New perspectives on the use of niacin in the treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Mechanism of action of niacin on lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Mechanistic studies of high-density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

Differences in metabolism of time-release and unmodified nicotinic acid: Explanation of the differences in hypolipidemic action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1303

10.1586/14779072.6.10.1303

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference